Review of trials currently testing treatment and prevention of COVID-19

Abstract

Background: As COVID-19 cases continue to rise globally, evidence from large randomized controlled trials is still lacking. Currently, numerous trials testing potential treatment and preventative options are being undertaken all over the world. Objectives: We summarized all registered clinical trials examining treatment and prevention options for COVID-19. Additionally, we evaluated the quality of the retrieved studies. Data sources: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European Union Clinical Trials Register were systematically searched. Study eligibility criteria: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. No language, country or study design restrictions were applied. We excluded withdrawn or cancelled studies and trials not reporting therapeutic or preventative strategies for COVID-19. Participants and interventions: No restrictions in terms of participants' age and medical background or type of intervention were enforced. Methods: The registries were searched using the term 'coronavirus' or 'COVID-19' from their inception until 26 March 2020. Additional manual search of the registries was also performed. Eligible studies were summarized and tabulated. Interventional trials were methodologically analysed, excluding expanded access studies and trials testing traditional Chinese medicine. Results: In total, 309 trials evaluating therapeutic management options, 23 studies assessing preventive strategies and three studies examining both were retrieved. Finally, 214 studies were methodologically reviewed. Interventional treatment studies were mostly randomized (n ¼ 150/198, 76%) and open label (n ¼ 73/198, 37%) with a median number of planned inclusions of 90 (interquartile range 40e200). Major categories of interventions that are currently being investigated are discussed. Conclusions: Numerous clinical trials have been registered since the onset of the COVID-19 pandemic. Summarized data on these trials will assist physicians and researchers to promote patient care and guide future research efforts for COVID-19 pandemic containment.

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults

“…Hydroxychloroquine was identified at the beginning of the pandemic as a candidate treatment based on preliminary data and quickly became the most tested treatment in the world for COVID-19. 40 41 However, many of the articles supporting hydroxychloroquine suffered from methodological shortcomings and were in fact non-informative. 42 Hydroxychloroquine has been widely promoted as soon as February 2020 as an effective drug by some scientists and politics, 43 leading to difficulties in recruiting patients in randomised clinical trials such as DisCoVeRy.…”

In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age

“…Our data show that in individuals over 60, expression of interferon-induced chemokines is reduced, possibly contributing to a reduction in transcripts for cytotoxic T and NK cells. Immune dysfunctions in older individuals are wellcharacterized [2,3,32,33] and likely contribute to poorer COVID-19 outcomes; results from clinical trials of type I and III interferons in severely ill patients are likely to further define the role of interferon signaling in older adults [48][49][50].…”

Smoking and COVID-19: Adding Fuel to the Flame

“…In addition, ribavirin and azvudine have shown some promising in vitro results for their efficacy against SARS-CoV-2, and it's in vivo efficacy is currently being tested in three ongoing clinical trials [171,172].…”